Israeli biotech Efranat Ltd. is developing an immunotherapy treatment approach for cancer, based on a glycoprotein named GcMAF (Globulin component Macrophage Activating Factor). Efranat has just raised $4.5 million and is conducting trials at Tel Hashomer’s Sheba Medical Center.
http://jewishbusinessnews.com/2014/11/21/israels-efranat-raises-4-5-million-to-acure-cancer/